| abstract |
Provided are pharmaceutical compositions comprising an engineered mammalian cell comprising a heterologous nucleic acid encoding an immunomodulator (such as immune checkpoint inhibitor). Further provided are methods of treating cancer using the pharmaceutical composition either singly or in combination with other technologies, such as Chimeric Antigen Receptor (CAR) or recombinant T cell receptor (TCR) modified T cell immunotherapy. |